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It is now recognized that for the benefits of new and effective therapies developed through basic and early 
translational science to be provided to patients with rare diseases, health systems will need to change. For example, 
Potter et al. state:  “There is a need for research to understand and improve health systems for rare diseases in order 
to ensure that new, efficacious therapies developed through basic and early translational science lead to benefits for 
patients. Such research must (i) focus on appropriate patient-oriented outcomes, (ii) include robust study designs that 
can accommodate real-world decision priorities, and (iii) involve effective stakeholder engagement strategies” [1]. 
One key stakeholder group which needs to be involved throughout the full lifecycle of a therapy, from pre-clinical 
studies to routine use or replacement with a new therapy, is patients with rare diseases and their caregivers. A recent 
scoping review identified a variety of opportunities for patients with rare diseases and their caregivers, and patient 
organizations to be involved in the lifecycle [2]. However, stakeholder engagement approaches in general have been 
criticised as being merely tokenistic [3-5] and, due to significant weaknesses in reporting, this review could not 
distinguish meaningful opportunities from tokenism [2]. In the specific case of rare diseases, it is not known exactly 
how patients and their caregivers may wish to be meaningfully engaged in the lifecycle of a therapy. Consequently, 
this study was designed to explore how Canadian patients with rare diseases and their caregivers believe they 
should be involved in the orphan drug lifecycle and to elucidate their opinions on their priorities for involvement. 
2 Background 
Patients with a specific disease have knowledge or information about their disease and the therapies that treat it, 
which may be helpful in decisions made along the lifecycle of a drug. For example, it has been suggested that 
patient/caregiver information or knowledge could help drive research and development decisions, decisions 
regarding clinical trials, risk-benefit considerations during regulatory review and decisions regarding funding or 
coverage of the drug [6-8]. This is particularly true for rare diseases. A rare disease has been defined as a life 
threatening, seriously debilitating, or serious and chronic condition affecting less than 1 in 2,000 people [9]. Many 
rare diseases are genetic and develop in childhood. They are often poorly understood and patients may spend years 
without an accurate diagnosis. Additionally, rare disease patients struggle with limited access to effective therapies 
due to the uncertainties that regulatory and coverage decision-makers face when assessing orphan drugs. While all 
decisions around new drugs are made under uncertainty, this uncertainty is magnified for orphan drugs [10]. This is 
a result of inadequate information on a product at the point of decision-making, which is itself a result of the 
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difficulties faced in conducting clinical trials [11] and the poorly understood natural history of rare diseases[12,13]. 
Published literature suggests that the involvement of patients and caregivers throughout the lifecycle of orphan drugs 
may help to reduce some of the uncertainties that decision-makers face and may improve patient access to new 
therapies [14]. In this study, three sessions involving rare disease patients and their caregivers were held to elicit 
information from them as to when and how they would like to be involved during the orphan drug lifecycle. 
3 Methods 
Taking a pragmatic qualitative research approach, the research team collaborated with the Canadian Organization 
for Rare Disorders (CORD) to facilitate data collection at two national CORD events [15]. CORD is comprised of 
over 80 patient organizations, providing access to patients and caregivers from a broad range of rare disease 
communities across Canada. Data were collected from a deliberative session hosted at each event. Subsequently, 
eight patients and caregivers, drawn from the deliberative sessions, participated in a webinar. The webinar allowed 
additional elucidation and validation of the findings. The deliberative sessions and webinar are described in detail 
below (Table 1). At both the sessions and the webinar, the orphan drug lifecycle was used to guide data collection, 
with patients and caregivers being asked how they felt they should be involved at each stage. 
Table 1.  Data sources. 
Characteristics Deliberative session 1 Deliberative session 2 Webinar 











How many participants 
were there? 
• 118 (46 patients, 
caregivers, and/or patient 
organization representatives) 
• 14 • 8 
Which disease communities 
were represented? 
• Cancers 
• Non-cancerous tumor 
disorders 
• Blood disorders 
• Metabolic disorders 
• Connective tissue disease 
• Endocrine disorders 
• Lung disorders 
• Secretory gland disorder 
• Epileptic encephalopathies 
• Vision disorders 
• Cancers 
• Non-cancerous tumor 
disorders 
• Blood disorders 
• Metabolic disorders 
• Connective tissue disease 
• Endocrine disorders 
• Lung disorders 
• Secretory gland disorder 
• Epileptic encephalopathies 
  
• Cancers 
• Non-cancerous tumor 
disorders 
• Blood disorders 
• Metabolic disorders 
• Connective tissue disease 
• Endocrine disorders 
• Lung disorders 
• Secretory gland disorder 
• Epileptic encephalopathies 
Where and when did the 
session take place? 
• At CORD’s Consultations 
Towards a Canadian Plan for 
Rare Diseases Conference 
(Toronto, November 2013) 
• Following CORD’s Rare 
Diseases Day Conference 
(Ottawa, March 2014) 
• Online (August 2015) 
What was the initial 
objective? 
• To identify what can be 
done to address the different 
• To identify how patients 
and families specifically can 
• To identify how patients 
and families believe they 
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uncertainties that exist 
throughout the orphan drug 
lifecycle 
contribute to reducing 
uncertainties 
should be involved 
throughout the orphan drug 
lifecycle, and 
• To validate the findings 
from the previous sessions 
What materials were 
provided? 
• Presentations on the orphan 
drug lifecycle, challenges of 
R&D and decision-making 
on orphan drugs, the 4 main 
uncertainties decision-
makers face, and existing 
policy tools that aim to 
reduce these uncertainties 
• A summary presentation on 
the orphan drug lifecycle, the 
4 main uncertainties 
decision-makers face, and 
existing policy tools that aim 
to reduce these uncertainties 
• A summary of existing and 
proposed opportunities for 
patients, caregivers, and 
patient organizations 
involvement identified in a 
scoping review and 
deliberative sessions 1 & 2 
Who facilitated the session? • One researcher • One researcher • One researcher 
How did information flow 
between the participants 
and the facilitator? 
• Two-way • Two-way • Two-way 
Were the sessions recorded 
and transcribed? 
• Yes • No • Yes 
Were field notes taken? • No • Yes • No 
Did the participants have 
the opportunity to review 
and clarify their responses? 
• No • Yes* • Yes 
* Participants subsequently participated in the Webinar where given the opportunity to comment on a summary presentation 
that included their responses from deliberative session 2  
 
3.1 Data analysis and interpretation 
Audio recordings and field notes from the sessions were analysed thematically using eclectic coding [16]. 
Descriptive and process coding were used to identify the topic (e.g., reimbursement decision-making) and the 
activity (e.g., providing input) respectively. This yielded a list of activities that patients and caregivers felt they 
could be involved in. However, additional information on these activities was obtained using values coding 
(reflecting perspectives, values, attitudes or beliefs about the specific type of engagement), evaluation coding 
(assigning judgements about the merit, worth, or significance of programs or policy) and emotion coding (labeling 
the emotions recalled and/or experienced by the patients/caregivers, or inferred by the researcher about the 
patient/caregiver). Illustrative examples of the results of the coding are presented in Online Resource 1. The 
activities were further grouped into Goals that patients and caregivers hoped to achieve by participating in those 
activities they had identified. 
Interpretation of the results was possibly influenced by the researcher’s background. AD has past experience 
volunteering with youth who have life-threatening, and sometimes rare, conditions.  To minimize bias and ensure 
the accuracy of the analysis, results were sent to patients and representatives from national rare disease organizations 




Three overall goals for patient/caregiver engagement emerged from the sessions. These were goals that patients and 
caregivers hoped to achieve through their involvement in different activities and included: (1) improved coverage 
decision-making, (2) improved care for patients, and (3) greater awareness of rare diseases. A detailed description of 
the ways in which patients and caregivers indicated they should participate in the orphan drug lifecycle, including 
examples from the transcripts, can be found in Tables A-1, A-2, and A-3 in Online Resource 2. The patients, 
caregivers and patient organization representatives who reviewed the study results had no disagreement with them 
nor additional information to add.  
The major themes are briefly summarised below according to the 3 goals. 
4.1 Improved coverage decision-making 
All three groups of patients and caregivers identified ways in which they could be involved that would improve 
existing reimbursement coverage decision-making. First, participants felt that patients should have early engagement 
in the clinical trial process, providing input into clinical trial design, including identifying and selecting meaningful 
outcome measures.  
“…because we’re talking about all the problems that happen after clinical trials are designed by people who know 
the science and the industry but don’t know the disease and that’s the problem: we’re dealing with the problem 
because we’re not included before the trial begins.” – Patient 1, session 1 
In addition, participants saw value in patients enrolling in registries and submitting patient-reported outcome 
measures (PROMs) during clinical trials in order to collect important quality of life data not captured by the clinical 
outcomes. As one caregiver, reflecting on the types of information collected, said: 
“And I mean there’s no measurement of cognitive function, there’s no measurement of all the benefits we’ve seen for 
her, but the study was on the kidneys.” – Caregiver 1, session 1 
Patients and caregivers recognized that registries can be burdensome and that not all patients or caregivers want to 
participate in them. They felt that, if possible, patient organizations should establish registries (e.g., natural history; 
drug side-effects; etc.), but recognized that registries are expensive and most patient organizations have limited 
resources. In fact, patients and caregivers expressed significant frustrations around their previous experiences where, 
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having enrolled and participated, the registries were shut down due to a lack of funding. In addition to funding, 
participants noted additional issues associated with registries, such as ethical issues: 
“So that’s something you might want to consider as a patient organization but again you’re dealing with the same 
questions: ethics, who is owning this, how do you guarantee the privacy and all of that?” – Patient 4, webinar 
In spite of these barriers, there was general agreement that the benefits of improved data collection outweigh the 
associated burden.   
“Rare disorders need another 10-15 years to come up with the evidence that [decision-makers] say we have to have 
and that’s why [they] deny us. Let’s give it to them.” – Patient 1, session 1 
Patients and caregivers also wanted to provide input into reimbursement decision-making. Some of the suggested 
areas of input were on the meaningfulness of the outcomes that are considered by decision-makers (“to better 
qualify what is meant by a benefit”); on treatment burden (“they thought it was just a matter of convenience”), 
including burden on the caregiver; on the benefit-harm ratio and their willingness to accept risk (“what risk you’re 
willing to take on should be taken into consideration”); and to identify and provide information that is missing from 
a drug submission before a negative decision is made based on insufficient data (“sometimes it could just be that a 
patient will write it out right, there’s something missing”).  
Some participants had experience providing input by completing patient submissions into CDR, but there was 
disagreement over the effectiveness of these submissions. Some felt that describing their experiences within the 
submission template was too difficult: 
“It’s very difficult on a piece of paper trying to explain why you think you need that drug or quality of life on a piece 
of paper.” – Patient 5, session 1 
Others felt that patients and patient organizations simply do not know how to use the submission form effectively. 
Regardless of these difficulties, participants felt that patients, caregivers, and patient organizations should still 
complete patient submissions. 
Patients and caregivers identified ways in which they should be involved revolving around managed access 
programs (MAPs).  MAPs are provisional coverage arrangements that aim to provide interim access while requiring 
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the generation of the information required to support a more definitive coverage decision within a set period of time 
[17]. Although none of the patients or caregivers had previous experience with MAPs, they were very interested in 
them as a way of providing patients with access to potentially beneficial orphan drugs while allowing for the 
collection of additional data on their effectiveness with real-world use. However, they felt that it is crucial to also 
have patient and caregiver input into the design of the programs to ensure that their needs and perspectives are 
considered. The arrangements need to be “systematic and fair on both sides” (Caregiver 4, session 2). 
Other ways in which patients and caregivers felt that they should be involved within the goal of improving coverage 
decision making ( and the following two goals) can be found in Tables A-1, A-2, and A-3 (Online Resource 2). 
4.2 Improved care for patients 
 Patients and caregivers discussed the highly heterogeneous nature of rare diseases and the importance of 
considering individual differences when treating a patient with a new orphan drug. They spoke about the fear and 
confusion that many patients and their caregivers have experience when starting a new treatment. 
Patients and caregivers suggested that patients should actively engage with their physician, choosing when to start 
and stop a new treatment. This approach would allow ongoing monitoring of their response to the treatment.  
“So, instead of having specific stopping criteria that it’s stated between the patient and their clinician, rather than a 
set rule within the drug plan criteria.” – Caregiver 1, session 1 
Some of the patients and caregivers felt that stopping criteria for a new drug based on a clinical measure (e.g., % 
increase in lung function) may be inappropriate as patients have very different experiences on drugs which are not 
captured by clinical outcomes (e.g., being able to walk up a set of stairs). They also supported the inclusion of a 
“buddy” system through which patients on a drug would provide support for new patients accessing the treatment.  
“I mean when we’re personally looking at options of treatment, one of them was really scary and I was really 
frightened.” – Patient 2, session 1 
Patients and caregivers also encouraged engagement with researchers to support development of new projects on 
potentially beneficial treatments.  
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“That’s how stem cell transplant therapy started…where the doctors were and the researchers were really 
encouraged by the parents…” – Caregiver 2, session 1 
None of the patients and caregivers had been involved in this manner but they were aware of patients and caregivers 
who had successfully piqued researchers’ interest as a result of which a new drug was developed for their rare 
disease. 
It was also suggested that patients and patient organizations should provide guidance to newly diagnosed patients. 
Patients described their own experiences of struggling to receive a diagnosis and, upon diagnosis, failing to receive 
proper care for a disease that is poorly understood. “This is what a patient organization helps you with” (Patient 3, 
session 2) stated one patient, who experienced negative health outcomes due to inappropriate prescribed treatment. 
Having a patient organization or, when no organization exists, a single patient to help guide individuals through the 
process was seen as helpful. As one patient suggested: 
“If you don’t know the right questions to ask, you won’t get information.”—Patient 2, session 2 
Patients and caregivers also felt that, as experts on their disease, they should provide input into the development of 
clinical practice guidelines (CPGs). Some had been involved in patient organizations that had made a request to a 
pharmaceutical company to be involved in the development of CPGs, only for the request to be denied.  One 
caregiver, reflecting on the stage at which patients might give input, suggested: 
“…maybe once they’ve drafted the guidelines they would be more comfortable.” – Caregiver 2, session 2 
4.3 Greater awareness of rare diseases 
 Patients and caregivers frequently spoke of the lack of awareness of rare diseases in Canada and the implications 
that this has for patient care and access to drugs. They felt that patient organizations should help to identify patients 
around the country and work  to increase awareness of the diseases.  
“And the patient organizations can help with that. When we increase our knowledge of where the patients are and 
let them know that, because a lot of the patient organizations don’t know who all of the people are who have that 
disease, that’s big” – Caregiver 2, webinar 
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“Because that is really important, spreading the word. Each individual can bring ten other individuals and, you 
know, your numbers will multiply when you’re doing a petition or letter campaign.” – Patient 4, webinar 
One way identified to accomplish this was through building relationships with all relevant stakeholders (e.g., 
funders, donors, physicians, etc.). 
“You build collaboration, you find common goals, and you work on these common goals.” – Patient 4, webinar 
The study participants felt that patient organizations should engage their members to increase their involvement, 
e.g., by following new research results and sharing them with their members, and should actively work to convince 
others to join in the advocacy efforts of patient organizations.  
It was felt that patients, caregivers, and patient organizations should promote the global Rare Disease Day on 
February 29th. Patient organizations should host conferences as well as attend international conferences. Finally, 
patients should present at these conferences and provide input into content planning for conferences.  
“Yes, in some cases you have the expert patients who can share their knowledge and give their perspective to other 
patients or even to doctors and health care providers.” – Patient 4, webinar 
Most of the patients and caregivers had participated in these opportunities and felt that it was important they 
continue to do so. 
4.4 Goals and the Orphan Drug Lifecycle 
After mapping each identified opportunity onto the orphan drug lifecycle, it became apparent that the goals of 
involvement identified by patients and caregivers transcend the individual stages, spanning the entire lifecycle (see 
Tables A-1, A-2, and A-3, Online Resource 2). 
5 Discussion 
This study demonstrated that patients with rare diseases and their caregivers are involved in various stages of the 
lifecycle of a drug for rare diseases. They are also prepared to be engaged in additional activity that would inform 
various aspects of rare disease management. This is an important addition to the literature on patient engagement 
which is limited, regardless of the disease. Studies have been published on patient involvement during individual 
clinical decision-making [18,19]; however, these are outside the scope of this study, which was a macro-level 
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analysis focused on large-scale processes (e.g. coverage decision-making). Some work has been published on the 
goals of patient involvement in health technology assessments and reimbursement decision-making, but these do not 
describe goals identified by the patients themselves [8,20].  
Several of the opportunities that patients and caregivers identified were ways in which they have already been 
involved (e.g., registries; patient submissions). These findings are consistent with the results of the scoping review 
[2]. The patients and caregivers also emphasized two opportunities for involvement that were not identified in the 
review: an increased level of input into reimbursement decision-making (e.g., benefit-harm ratio acceptability) and 
participation in managed access programs. Some of the barriers to involvement that patients and caregivers 
identified in this study are also reflective of the scoping review findings, which found a significant gap in reporting 
on existing opportunities in Canada and limited reporting around the details of involvement. This gap prevents 
assessment of potential tokenism or the impact of involvement. Other research has also documented this lack of 
reporting [8]. Patients and caregivers in this study were concerned about tokenism and ensuring their input has an 
impact. Addressing these barriers is important for improving existing opportunities for involvement and for 
introducing new ways to involve patients and caregivers. 
5.1 Strengths and weakness of the study 
Both deliberative sessions were conducted at national events hosted by CORD. It is possible that individuals who 
choose to participate in these events are different from those who do not and are not representative of the rare 
disease population in Canada. However, CORD is comprised of over 80 different rare disease patient organizations 
and encourages patients and caregivers to attend their events by covering travel costs, increasing the likelihood that 
the sample was unbiased. Another limitation of the study is that only one researcher (AD) coded the transcripts. 
However, the results of the analysis were reviewed by two additional researchers (DM; TS) who also attended the 
sessions and webinar. 
6 Conclusion 
Patients and their caregivers are eager to participate throughout the orphan drug lifecycle and improving coverage 
decision-making is a priority. They also want to ensure that their involvement is meaningful and valued by other 
stakeholders. Future research is needed into developing and mobilizing mechanisms that will allow for patient and 
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